No dose adjustment of metformin or substrates of organic cation transporters ( OCT )1 and OCT2 and multidrug and toxin extrusion protein ( MATE )1/ 2K with fostemsavir coadministration based on modeling approaches
Pharmacology Research & Perspectives · 2024
DOI: 10.1002/prp2.1238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2024. Verfasst von Dung Nguyen und 6 weiteren Autor:innen. Beteiligte Einrichtung: GlaxoSmithKline, Collegeville, Pennsylvania, USA. Hauptthemen laut MEDLINE: Metformin, Drug Interactions, Organic Cation Transport Proteins, Organic Cation Transporter 2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Fostemsavir is an approved gp120‐directed attachment inhibitor and prodrug for the treatment of human immunodeficiency virus type 1 infection in combination with other antiretrovirals (ARVs) in heavily treatment‐experienced adults with multi‐drug resistance, intolerance, or safety concerns with their current ARV regimen. Initial in vitro studies indicated that temsavir, the active moiety of fostemsavir, and its metabolites, inhibited organic cation transporter (OCT)1, OCT2, and multidrug and toxin extrusion transporters (MATEs) at tested concentration of 100 uM, although risk assessment based on the current Food and Drug Administration in vitro drug–drug interaction (DDI) guidance using the mechanistic static model did not reveal any clinically relevant inhibition on OCTs and MATEs. However, a DDI risk was flagged with EMA static model predictions. Hence, a physiologically based pharmacokinetic (PBPK) model of fostemsavir/temsavir was developed to further assess the DDI risk potential of OCT and MATEs inhibition by temsavir and predict changes in metformin (a sensitive OCT and MATEs substrate) exposure. No clinically relevant impact on metformin concentrations across a wide range of temsavir concentrations was predicted; therefore, no dose adjustment is recommended for metformin when co‐administered with fostemsavir.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GlaxoSmithKline, Collegeville, Pennsylvania, USA.
- GlaxoSmithKline, Ware, UK.
- Allucent, Cary, North Carolina, USA.
ORCID-Profile: Dung Nguyen
Zitieren
APA
Nguyen, D., Miao, X., Taskar, K., Magee, M., Gorycki, P., Moore, K., & Tai, G. (2024). No dose adjustment of metformin or substrates of organic cation transporters ( OCT )1 and OCT2 and multidrug and toxin extrusion protein ( MATE )1/ 2K with fostemsavir coadministration based on modeling approaches. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1238
Vancouver
Nguyen D, Miao X, Taskar K, Magee M, Gorycki P, Moore K, et al. No dose adjustment of metformin or substrates of organic cation transporters ( OCT )1 and OCT2 and multidrug and toxin extrusion protein ( MATE )1/ 2K with fostemsavir coadministration based on modeling approaches. Pharmacology Research & Perspectives. 2024. doi:10.1002/prp2.1238
BibTeX
@article{Nguyen2024,
author = {Nguyen, Dung and Miao, Xiusheng and Taskar, Kunal and Magee, Mindy and Gorycki, Pete and Moore, Katy and Tai, Guoying},
title = {No dose adjustment of metformin or substrates of organic cation transporters ( OCT )1 and OCT2 and multidrug and toxin extrusion protein ( MATE )1/ 2K with fostemsavir coadministration based on modeling approaches},
journal = {Pharmacology Research & Perspectives},
year = {2024},
doi = {10.1002/prp2.1238}
}
EUVIMED